Prasugrel in der Akut- und Nachbehandlung des akuten Koronarsyndroms: Wie ist der aktuelle Stand?

Schlüsselwörter

Prasugrel - Clopidogrel - Akutes Koronarsyndrom

Keywords

Prasugrel - Clopidogrel - acute coronary syndrome

Literatur

• 1 Abraham N S, Hlatky M A, Antman E M. et al . ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.  Circulation. 2010;  122 2619-2633
• 2 Bhatt D L, Cryer B L, Contant C F. et al . Clopidogrel with or without omeprazole in coronary artery disease.  N Engl J Med. 2010;  363 1909-1917
• 3 Bonello L, Tantry U S, Marcucci R. et al . Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.  J Am Coll Cardiol. 2010;  56 919-933
• 4 Mega J L, Close S L, Wiviott S D. et al . Cytochrome p-450 polymorphisms and response to clopidogrel.  N Engl J Med. 2009;  360 354-362
• 5 Mega J L, Close S L, Wiviott S D. et al . Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.  Circulation. 2009;  119 2553-2560
• 6 Mega J L, Close S L, Wiviott S D. et al . Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.  Lancet. 2010;  376 1312-1319
• 7 Mehta S R, Tanguay J F, Eikelboom J W. et al . Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.  Lancet. 2010;  376 1233-1243
• 8 Montalescot G, Sideris G, Cohen R. et al . Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.  Thromb Haemost. 2010;  103 213-223
• 9 National institute for for health and clinical excellence .prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention. http://www.nice.org.uk/nicemedia/pdf/PrasugrelFADToPMForAppealPeriod.pdf.  2009
• 10 Price M J. Standard versus high-dose clopidogrel according to platelet function testing After PCI: results of the GRAVITAS Trial. Late breaking clinical trials III. Chicago: American Heart Association (AHA); 2010
• 11 Serebruany V L. Mortality in the TRITON trial: update from the FDA prasugrel action package.  Am J Cardiol. 2010;  105 1356-1357
• 12 Sibbing D, Braun S, Morath T. et al . Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.  J Am Coll Cardiol. 2009;  53 849-856
• 13 Trenk D, Hochholzer W, Fromm M F. et al . Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.  J Am Coll Cardiol. 2008;  51 1925-1934
• 14 Widimsky P, Wijns W, Fajadet J. et al . Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries.  Eur Heart J. 2010;  31 943-957
• 15 Wijns W, Kolh P, Danchin N. et al . Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).  Eur Heart J. 2010;  31 2501-2555
• 16 Wiviott S D, Antman E M, Braunwald E. Prasugrel.  Circulation. 2010;  122 394-403
• 17 Wiviott S D, Braunwald E, Angiolillo D J. et al . Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.  Circulation. 2008;  118 1626-1636
• 18 Wiviott S D, Braunwald E, McCabe C H. et al . Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.  Lancet. 2008;  371 1353-1363
• 19 Wiviott S D, Braunwald E, McCabe C H. et al . Prasugrel versus clopidogrel in patients with acute coronary syndromes.  N Engl J Med. 2007;  357 2001-2015
• 20 Wiviott S D, Trenk D, Frelinger A L. et al . Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.  Circulation. 2007;  116 2923-2932